2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study

MLA

P. Maes, et al. “2095 Survival Benefit, Safety, and Prognostic Factors for Outcome with Regorafenib (RE) in Patients (Pts) with Pretreated Metastatic Colorectal Cancer (MCRC). Main Analyses of the REBECCA Study.” European Journal of Cancer, vol. 51, Sept. 2015, p. S360. EBSCOhost, https://doi.org/10.1016/s0959-8049(16)31017-6.

APA

P. Maes, Jean-François Morère, Jennifer Wallet, J.L. Wendling, Benjamin Linot, Bernard Paule, C. De La Fouchardiere Fontaniere, Stéphanie Clisant, Pascal Burtin, David Tougeron, Jérôme Dauba, C. Becuwe, Pierre Michel, P.L. Etienne, J.M. Phelip, Antoine Hollebecque, Louis-Marie Dourthe, T. Andre, L. Mineur, & Antoine Adenis. (2015). 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. European Journal of Cancer, 51, S360. https://doi.org/10.1016/s0959-8049(16)31017-6

Chicago

P. Maes, Jean-François Morère, Jennifer Wallet, J.L. Wendling, Benjamin Linot, Bernard Paule, C. De La Fouchardiere Fontaniere, et al. 2015. “2095 Survival Benefit, Safety, and Prognostic Factors for Outcome with Regorafenib (RE) in Patients (Pts) with Pretreated Metastatic Colorectal Cancer (MCRC). Main Analyses of the REBECCA Study.” European Journal of Cancer 51 (September): S360. doi:10.1016/s0959-8049(16)31017-6.